Imaging the Vesicular Acetylcholine Transporter Using 18F-FEOBV PET in Parkinsons Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-08-08

Study Completion Date

2022-08-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with Parkinson's disease (PD) often display symptoms, such as constipation, due to denervation of the cholinergic nerves in the gut. It has been hypothesized that PD initiates in the gut years prior to diagnosis. To gain a detailed understanding of the early stages of PD, techniques for quantification of cholinergic nerves are needed. The PET tracer 18F-FEOBV binds specifically to the vesicular acetylcholine transporter, situated in presynaptic cholinergic nerve terminals. The investigators will investigate 18F-FEOBV uptake in the brain and internal organs of 15 patients with moderate-stage PD and compare to 15 healthy controls. Furthermore, findings are correlated to validated clinical tests of the autonomic nervous system. The aim is to validate 18F-FEOBV PET/CT as a clinical imaging modality to diagnose parasympathetic denervation in PD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol

NCT02952391

Parkinson's Disease

UNKNOWN

PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease

NCT02801110

Idiopathic Parkinson's Disease

UNKNOWN

Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease

NCT00737217

Parkinson's Disease

COMPLETED

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

NCT01461109

Parkinson Disease Alzheimer Disease

COMPLETED PHASE1

Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations

NCT00302146

Parkinson Disease Gaucher Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Parkinsons disease

Disease duration \> 4 years, Hoehn \& Yahr stage 2-3, 50-85 years old

No interventions assigned to this group

Healthy controls

50-85 years

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parkinsons disease, disease duration \> 4 years, Hoehn \& Yahr stage 2-3

Exclusion Criteria

* Significant neurological diseases (e.g. stroke, tumor)
* Significant psychiatric disease
* Previous major surgery on thoracic and/or abdominal organs
* Significant medical disease (e.g. heart- or liver failure)
* Inflammatory bowel disease
* Gluten intolerance
* Diabetes
* Magnetic Resonance (MR) contraindications (metal in body, claustrophobia)
* Allergy to CT-contrast fluid
* Pacemaker
* Any current or previous cancer involving internal organs
* Peripheral neuropathy (except Parkinsons disease related)

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes